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The role of IRF7 in the host response to lymphocytic choriomeningitis virus (LCMV) Armstrong 53b
infection of mice was investigated. Intracranial infection of IRF7 KO mice was associated with delayed
onset of LCM, increased survival and signiﬁcantly reduced expression of the Ifng gene in the brain but
not in the periphery. IRF7 KO mice showed impaired control of LCMV replication and delayed clearance
of LCMV. Similar numbers of activated anti-LCMV-GP33–41 CD8þ T cells were present in the brain and
spleens of infected WT and IRF7 KO mice. While plasma IFN-b was increased to similar levels, IFN-a
was markedly reduced in IRF7 KO compared with WT mice. Compared with IFN-b, IFN-a was a less
potent inhibitor of LCMV infection in vitro. In conclusion, IRF7 (1) is required for the early innate control
of LCMV infection, likely through the regulation of the appropriate type I IFN response, and (2) is not
required for the antiviral CD8þ T cell-dependent clearance of LCMV from infected tissues.
& 2013 Elsevier Inc. All rights reserved.Introduction
Interferon regulatory factor (IRF)7 belongs to a family of
transcription factors, which contains nine members (IRF1-9)
(Taniguchi et al., 2001). Amongst the IRFs, IRF3 and IRF7 play a
critical role in the host response to virus infection regulating the
expression of the type I IFN (IFN-I), IFN-b as well as a number of
IFN-a genes (Marie et al., 1998; Sato et al., 1998, 2000). The host
detects viral invasion by different types of pattern recognition
receptors (PRR) that recognize pathogen-associated molecular
patterns (PAMPs) present on microbial proteins or nucleic acids
(reviewed in (Kawai and Akira, 2006; Takeuchi and Akira, 2007)).
Recognition of virus-derived single- or double- stranded RNA by
the endosomal Toll-like receptors (TLR) TLR3, TLR7, TLR8 and
TLR9 or the cytoplasmic retinoic acid-inducible gene I (RIG-I)-like
receptors (RLRs) melanoma differentiation-associated gene 5
(MDA5) and RIG-I results in the activation of IRF3 and IRF7
leading to the production of IFN-I. The production of IFN-I occurs
in two steps in which IFN-b and IFN-a4 are initially produced via
an IRF3-dependent pathway (Marie et al., 1998; Sato et al., 1998).
These bind to the IFN-I receptor (IFNAR) to activate a subset of
IFN-stimulated genes (ISGs) including IRF7. The subsequentll rights reserved.
ience G08, Maze Crescent,
1 2 9351 5858.
. Campbell).activation of IRF7 leads to further IFN-a/b production, and
subsequent transcription of a large set of interferon stimulated
genes that interfere with various steps in virus replication cycle,
inhibiting infection and viral spread (reviewed in (Samuel, 2001;
Sen, 2001)). In addition to its antiviral effects, IFN-I are also
important for differentiation and maturation of antigen present-
ing cells (APCs), the activation of T- and B- cells and also promote
the development and survival of the CD8þ cytotoxic T cells (CTL)
(for reviews see (Alshariﬁ et al., 2008; Seo and Hahm, 2010)).
Lymphocytic choriomeningitis virus (LCMV) is a bisegmented
ssRNA virus belonging to the Arenaviridae family and is consid-
ered an emerging human pathogen (Tyler, 2009). Human trans-
mission has been shown to occur in utero, upon transplantation
with infected organs or upon contact with infected laboratory and
wild animals. Congenital LCMV infection is abortifacient and a
fetal teratogen commonly manifested as chorioretinitis, hydro-
cephalus and microcephaly or macrocephaly. LCMV infection of
adults can lead to the development of fever, malaise, headaches,
seizures and in some cases fatal meningitis.
LCMV infection in its natural host the mouse is a widely studied
model for virus host interactions (reviewed in (Buchmeier et al.,
1980; Kang and McGavern, 2008)). In adult WT mice, peripheral
infection with LCMV-Armstrong (Arm) has little clinical impact
with CD8þ T cell mediated clearance of the virus by 10–12 days
post infection. In contrast, intracranial (i.c.) infection of WT mice
with LCMV-Arm results in a lethal neurological disease (termed
LCM) with characteristic seizures and mononuclear cell inﬁltrates
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CD8þ T cells produce cytokines and chemokines that mediate
extravasation of myelomonocytic cells including neutrophils and
monocytes, which lead to vascular leakage and acute lethality (Kim
et al., 2009). LCMV itself is a relatively non-cytopathic virus and in
line with this, either peripheral or i.c. inoculation of LCMV-Arm in T
cell deﬁcient RAG or SCID mice results in persistent infection
without untoward physical effects (Buchmeier et al., 1980; Kang
and McGavern, 2008).
IFN-I are important for mediating the control of LCMV as
IFNAR KO mice show enhanced LCMV replication and develop
persistent infection following i.p. infection (Muller et al., 1994; Ou
et al., 2001). In addition, mice lacking IFNAR (Ou et al., 2001) or
the IFN-I signaling molecules STAT2 or IRF9 (Hofer et al., 2012) or
treated with anti-IFN-a/b serum (Sandberg et al., 1994b) do not
develop LCM after i.c. infection with LCMV. The molecular path-
way leading to IFN-I induction during LCMV infection has not
been fully clariﬁed. However, IFN-I induction by recognition of
LCMV via either TLR7/9 or RIG-I/MDA5 was reported to be fully
dependent on IRF7, but not IRF3 (Edelmann et al., 2004; Jung
et al., 2008; Zhou et al., 2010). Previous studies revealed that mice
deﬁcient for IRF7 are vulnerable to infection with viruses includ-
ing West Nile virus (WNV) (Dafﬁs et al., 2008) and Herpes simplex
virus (HSV) type 1 and Encephalomyocarditis virus (EMCV)
(Honda et al., 2005). Importantly, the increased susceptibility to
these viruses was attributed to the depressed production of IFN-I
due to the absence of IRF7. We have shown previously that the
expression of the Irf7 gene is highly upregulated in a variety of
cells in the CNS following i.c. LCMV infection of mice (Ousman
et al., 2005). This IRF7 response to LCMV infection is dependent
on IFN-I indicating that as in the periphery, mutual stimulation of
IRF7 and IFN-I is required for effective antiviral responses in the
CNS. In view of the crucial role that IFN-I play in the innate and
adaptive immune response to LCMV infection the objective of the
present study was to determine the role of IRF7 in this response
and the control of LCMV infection in mice.Results
Delayed onset and partial protection from lethal LCM in IRF7 KO mice
Following i.p. infection with LCMV-Arm, both WT and IRF7 KO
mice developed only mild clinical signs such as rough fur and
reduced activity and all mice survived (Fig. 1A). In contrast to i.p.
infected WT mice that showed no weight loss, a transient weight
loss occurred in i.p. infected IRF7 KO mice starting at day 6 post-
infection (Fig. 1B). However, this weight loss was not signiﬁcantFig. 1. IRF7-deﬁciency impacts the clinical course following i.c. but not i.p. LCMV
with a total number of 25 WT mice and 25 IRF7 KO mice. Mice were infected i.c. w
postinfection (PI). For signiﬁcance, * po0.0001 compared with WT mice as determined
determined following i.p. infection. Data are shown as mean7SEM. For signiﬁcance, *po
Mann–Whitney-U-test.and by day 15 postinfection IRF7 KO mice had recovered. In
addition, by day 30 postinfection IRF7 KO mice had gained
signiﬁcantly more weight than infected WT mice. In contrast to
i.p. infection, i.c. infection of WT mice with LCMV-Arm resulted in
neurological disease with a range of symptoms consistent with
LCM including characteristic convulsive seizures, hunched posture,
rough fur, reduced activity and weight loss with death ensuing
between day 6 to 7 postinfection (Fig. 1A). Similarly infected IRF7
KO mice also showed these symptoms including convulsive sei-
zures and weight loss, but the onset of these symptoms was
delayed by one day and death occurred between day 7 and 11.
Furthermore, after i.c. infection, IRF7 KO mice showed a signiﬁ-
cantly higher survival rate (30%) than WT mice (7%) (Fig. 1A). The
surviving IRF7 KO mice recovered and showed no overt clinical
signs of infection. Thus, the loss of IRF7 delays the onset and
protects some but not all mice from lethal LCM following i.c.
infection with LCMV.Analysis of cerebral cytokine and chemokine gene expression during
i.c. LCMV infection reveals a defect in Ifng gene expression in the
absence of IRF7
Previous studies have shown the robust induction of a number
of proinﬂammatory cytokine and chemokine genes in the brain of
LCMV-infected mice inoculated i.c. which is associated with the
progression of LCM (Asensio and Campbell, 1997; Campbell et al.,
1994). To further investigate the basis for the increased survival
of IRF7 KO mice following i.c. infection, we next examined the
expression of a number of cytokine and chemokine genes in the
brain (Fig. 2). Consistent with previous ﬁndings, the expression of
CCL1, CCL2, CCL3, CCL5 CCL6, CCL7, CXCL2, CXCL10, IFN-g, IL-1a,
IL-1b and TNF-a mRNAs was increased signiﬁcantly at day 7 and
sustained at day 8 postinfection in the brain fromWT mice. In the
brain of i.c. infected IRF7 KO mice the expression of all these
cytokine and chemokine mRNA transcripts was also signiﬁcantly
increased on day 7 postinfection. While the levels of CCL6,
CXCL10 and IFN-g mRNAs remained unchanged on day 8 post-
infection in IRF7 KO mice, the expression of the CCL2, CCL3, CCL7,
TNFa, IL-1a and IL-1b mRNAs was decreased signiﬁcantly com-
pared with day 7 postinfection. The expression of the IFN-gmRNA
was signiﬁcantly lower in the brain from infected IRF7 KO mice
compared with infected WT mice. In total, these ﬁndings indi-
cated that with the exception of Ifng gene expression which was
signiﬁcantly lower in IRF7 KO mice, the cerebral expression of a
number of proinﬂammatory cytokine and chemokine genes was
increased to similar levels in WT and IRF7 KO mice following i.c.
infection with LCMV.infection. (A) Survival outcome. Three independent experiments were performed
ith 200 PFU LCMV-Arm or i.p. with 500 PFU of LCMV and monitored each day
by Logrank Test. (B) Weight change. The weight of 9 WT and 9 IRF7 KO mice was
0.05 compared with corresponding sham-infected control mice as determined by
Fig. 2. Cerebral cytokine and chemokine gene expression in WT and IRF7 KO mice. The expression of the cytokine and chemokine mRNA transcripts including CCL1,
CCL2, CCL3, CCL5 CCL6, CCL7,CXCL2, CXCL10, IFN-g, IL-1a, IL-1b and TNF-a were analyzed in the brain of i.c infected WT and IRF7 KO mice on day 7 (n¼3 for each
genotype) and day 8 (n¼3 for WT mice, n¼5 for IRF7 KO mice) postinfection. Total RNA (10 mg) was analyzed by RPA as described in the Materials and methods section.
The individual cytokine and chemokine mRNA levels were normalized to that of the housekeeping gene L32 and shown as mean7SEM. For signiﬁcance: *po0.05
compared with uninfected mice or compared with respective time point in WT mice as determined by Mann-Whitney-U-test.
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mice
In order to determine whether IRF7 was important for
controlling viral spread, we next investigated the presence of
LCMV-NP RNA in infected mice. Following i.c. infection of WT
mice, high levels of viral RNA were present in the brain at day
4 and 6 postinfection and in the spleen but not detectable in the
liver, kidney or lung at day 4 postinfection (Fig. 3A). In similarly
infected IRF7 KO mice, LCMV-NP RNA was present at high levels
in the brain and spleen at day 4 and 6 but thereafter decreased in
surviving animals being detectable in the brain at day 15 but not
at day 30 postinfection, and was also undetectable in the spleen
by day 15 postinfection (Fig. 3A). In contrast to infected WT mice,
in infected IRF7 KO mice, LCMV-NP RNA was also present in the
liver, kidney and lung at day 4 and 6 postinfection but was
undetectable by day 15 (liver and kidney) or day 30 (lung)
postinfection (Fig. 3A). These ﬁndings indicated that in mice
lacking IRF7 there was increased tissue tropism and burden with
LCMV but eventual clearance of the infection.
To analyze further the dynamics of LCMV infection and its
control by IRF7, WT or IRF7 KO mice were inoculated i.p. with
LCMV-Arm (Fig. 3B). In WTmice, a low level of LCMV-NP RNA was
present in the spleen at day 4 postinfection only, but was not
detectable in the brain, liver and kidney at any time postinfection
(Fig. 3B). However, in IRF7 KO mice, LCMV-NP RNA was detect-
able in the spleen at a signiﬁcant higher level (50% higher) on day
4 and thereafter decreased but remained detectable out to day 15
postinfection (Fig. 3B). Moreover, in the liver and kidney, a high
level of LCMV-NP RNA was present at day 4, decreased at day
8 and 15 and was undetectable at day 30 postinfection (Fig. 3B).
LCMV-NP RNA was also present in the brain of LCMV-infected
IRF7 KO mice at day 8 and 15 postinfection. These ﬁndings
conﬁrm that IRF7 KO mice are defective in the ability to control
systemic LCMV infection with extensive tissue spread of the virus
following systemic infection, yet, clearance of the infection is
achieved.To conﬁrm that the presence of LCMV-NP RNA corresponded
to infectious virus, plaque assays were performed on tissue
lysates of liver and spleen. Infectious virus was not detectable
in the liver (Fig. 3C) of i.p. infected WT mice, but was present in
the spleen at day 4 postinfection and was undetectable on day 30
(Fig. 3D). Compared with infected WT mice, a high virus titer was
found in both liver and spleen lysates from infected IRF7 KO mice
at day 2, 4 and 8 postinfection, but was not detectable at day 30
(Fig. 3C and D). Similar to the RPA results, the plaque assay
showed that deﬁciency in IRF7 resulted in the early spread of
LCMV with more sustained infection in the liver and spleen.
Together the results demonstrate that IRF7 plays an important
role in limiting virus spread and replication following infection
with LCMV; however, IRF7 is not essential for the clearance of
LCMV from the host.
Dysregulated tissue Ifn gene expression and serum IFN levels in IRF7
KO mice
IRF7 is a positive regulator of IFN-I production in the anti-viral
host response (Honda et al., 2005). We next investigated the role
of IRF7 in the qualitative and quantitative expression of the IFN-I
as well as IFN-g response to LCMV infection. Following i.c.
infection with LCMV, IFN-b mRNA was increased signiﬁcantly at
day 6 in the brain of WT mice, but the level of IFN-bmRNA in IRF7
KO mice was signiﬁcantly increased at both day 4 and day
6 postinfection (Fig. 4A and B). Since IRF7 KO mice have delayed
disease onset we examined IFN-b mRNA levels at the maximum
disease point for each genotype. The results showed that IFN-b
mRNA was signiﬁcantly increased to similar levels in both WT
and IRF7 KO mice following i.c. infection (Fig. 4C and D). Follow-
ing i.p. infection with LCMV, IFN-b mRNA was induced at day
2 and 4 postinfection in the spleen of both WT and IRF7 KO mice
albeit at signiﬁcantly lower levels in IRF7 KO mice (Fig. 4E and F).
These ﬁndings indicated that IRF7 is required for the optimal
expression of IFN-b mRNA in the spleen but not the brain
following LCMV infection.
Fig. 3. Impaired control of virus replication and spread in IRF7 KO mice following infection with LCMV. (A) LCMV-NP RNA was detected by RPA in the brain, liver,
kidney, spleen and lung of WT mice and IRF7 KO mice following i.c. infection with LCMV (A) and in the brain, liver, kidney and spleen of WT mice and IRF7 KO mice
following i.p. infection with LCMV (B). Total RNA (10 mg) was analyzed by RPA as described in the Materials and methods section. Expression of LCMV-NP RNA were
normalized to the housekeeping gene L32 and shown as mean7SEM. Experiments were performed twice (n¼6 in total at each time point). (C) Plaque assay was
performed on tissue lysates prepared from liver and spleen of WT mice (n¼3) and IRF7 KO mice (n¼3) infected i.p. with LCMV as described in the Materials and methods
section. For signiﬁcance: *po0.05 compared with respective time point in WT mice as determined by Mann–Whitney U-test.
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WT and IRF7 KO mice (Fig. 4A–D) and the spleen of IRF7 KO mice,
but was present at a very low level in the spleen of WT mice(Fig. 4E and F). Following i.c. infection with LCMV, IFN-g mRNA
increased to high levels at day 6 postinfection in the brain of WT
mice and IRF7 KO mice. However, the magnitude of this increase
Fig. 4. Absence of IRF7 is associated with altered IFN-I and IFN-g following infection with LCMV. Autoradiograph showing IFN-b and IFN-g mRNA levels in the brain
(A) and in the spleen (E) of WT mice and IRF7 KO mice infected i.c. or i.p., respectively, with LCMV. Experiments were performed twice (n¼6 in total at each time point).
(C) Autoradiograph showing IFN-b and IFN-gmRNA levels in the brain at the terminal stage of LCM (day 6 for WT mice and day 7 for IRF7 KO mice) for WT mice (n¼5) and
IRF7 KO mice (n¼5) infected i.c. with LCMV. Total RNA (10 mg) was analyzed by RPA as described in the Materials and methods section. Quantiﬁcation of IFN-b and IFN-g
RNA in the brain (B&D, respectively) or spleen (F). Values were normalized to the housekeeping gene L32 and shown as mean7SEM. (G) IFN-a, IFN-b and IFN-g ELISA was
performed on the serum from WT mice (n¼3) and IRF7 KO mice (n¼3) following i.p. infection with LCMV. Values represent mean 7SEM. For signiﬁcance: *po0.05
compared with uninfected mice or compared with respective time point in WT mice as determined by Mann–Whitney-U-test.
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expression IFN-g mRNA in the brain remained at a signiﬁcantly
lower level in IRF7 KO mice than WT mice when both genotypes
were compared at the maximum clinical disease stage (Fig. 4C
and D). Following i.p. infection with LCMV, IFN-g mRNA was
increased to similar levels in the spleen of WT mice at day 2,
4 and 8 postinfection (Fig. 4E and F). IFN-g mRNA was also
increased markedly in the spleen of infected IRF7 KO mice at day
2, but was signiﬁcantly higher at day 4 before decreasing to
similar levels at day 8 postinfection (Fig. 4E and F). In summary
these ﬁndings indicated that the absence of IRF7 during LCMV
infection has opposing effects on Ifng gene expression which was
decreased in the brain but increased in the spleen when com-
pared with WT mice.
The possible contribution of IRF7 to the regulation of systemic
IFN-I and IFN-g production during LCMV infection was studied
next. Following i.p. infection, high levels of IFN-a were present on
day 2 postinfection in serum from WT mice but was below the
detection limit in serum from similarly infected IRF7 KO mice
(Fig. 4G). However, IFN-b was present at similar levels in serum
from both WT and IRF7 KO mice at day 2 postinfection (Fig. 4G).
The level of IFN-g was increased at day 4 and further increased at
day 8 postinfection in serum from WT mice (Fig. 4G). In IRF7 KO
mice, IFN-g also increased markedly at day 4 but at a signiﬁcantly
higher level than in WT mice. Taken together, these resultsindicated that IRF7 was essential for LCMV-induced IFN-a pro-
duction, but was not required for systemic IFN-b and IFN-g
production.
IFN-b is more effective than IFN-a to limit LCMV replication in vitro
The increased virus load in LCMV-infected IRF7 KO mice
correlated with a dysregulated IFN-I response where IFN-a
production was almost absent but IFN-b production remained
largely intact. The relative effectiveness of different IFN-I to
inhibit LCMV replication is unknown. Therefore we next com-
pared the ability of IFN-a versus IFN-b to inhibit LCMV replication
in RAW264.7 cells. High virus production was detected in the
LCMV infected RAW264.7 cells in the absence of IFN-I treatment
(Fig. 5A). At a MOI of 0.5, while both IFN-a and IFN-b mediated
dose-dependent inhibition of LCMV production, IFN-b was more
potent than IFN-a with complete inhibition of virus production
from 100 U/ml for IFN-b compared with 1000 U/ml for IFN-a
(Fig. 5A). The combination of IFN-a and IFN-b caused a similar
dose-dependent inhibition of LCMV replication as found with IFN-
b alone (Fig. 5A). At the higher MOI of 1, signiﬁcant inhibition of
LCMV replication was not achieved until 1000 U/ml for IFN-a
compared with 10 U/ml for IFN-b. The combination of IFN-a and
IFN-b was signiﬁcantly less effective than IFN-b in inhibiting
LCMV replication at the low dose of 10 U/ml but effectively
Fig. 5. IFN-b was more effective than IFN-a in inhibiting LCMV production. RAW264.7 cells were infected with LCMV at an MOI of 0.5 (A) or an MOI of 1.0 (B) and
treated with increasing concentrations of IFN-a, IFN-b and IFN-a plus IFN-b. Culture medium was collected and plaque assay was performed as described in the Materials
and methods section. For signiﬁcance versus non-treated controls: ^, po0.05 for IFN-a treatment; #, po0.05 for IFN-b treatment; and *, po0.05 for combined IFN
treatment. For signiﬁcance, IFN-a versus IFN-b treatment: þ , po0.05; IFN-a versus combined IFN treatment: x, po0.05; and IFN-b versus combined IFN treatment: v,
po0.05. Autoradiograph (C) showing PKR, IRF7, ISG15 and CXCL10 mRNA levels in the RAW264.7 treated with increasing concentration of IFN-a or IFN-b. Total RNA (3 mg)
was analyzed by RPA as described in the Materials and methods section. Quantiﬁcation of PKR, IRF7, ISG15 and CXCL10 mRNA levels (D). Values were normalized to the
housekeeping gene L32 and the results shown as mean7SEM. For signiﬁcance treated versus non-treated controls: #, po0.05 for IFN-a treatment; *, po0.05 for IFN-b
treatment. For signiﬁcance of IFN-a versus IFN-b treatment: ^, po0.05 as determined by Mann–Whitney U-test.
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studies indicated that the IFN-a preparation used was signiﬁ-
cantly less potent than IFN-b at inhibiting LCMV replication in
RAW264.7 cells.
The antiviral actions of IFN-I are mediated via the induction
of a number of cellular genes that encode proteins, some of
which directly interfere with different stages of the viral
replication cycle (Samuel, 2001; Sen, 2001). We next asked
whether the inhibition of LCMV replication observed for IFN-a
and IFN-b reported above correlated with the ability of these
IFN-I to induce a number of IFN-stimulated genes (ISGs) in
RAW264.7 cells. The results (Fig. 5C and D) indicated thatwhile both IFN-I induced a dose-dependent increase in the
expression of PKR, IRF7, ISG15 and CXCL10, IFN-a was sig-
niﬁcantly less potent than IFN-b at the lower doses of 10 U/ml
(IRF7) and 10 and 25 U/ml (ISG15 and CXCL10). However, at
higher doses (100 and 250 U/ml) the levels of the ISG mRNA
transcripts induced were similar for both IFN-a and IFN-b.
These ﬁndings indicated that at low doses, IFN-a is signiﬁ-
cantly less potent than IFN-b at inducing speciﬁc ISGs in
RAW264.7 cells. However, at higher doses where IFN-a was
relatively ineffective at inhibiting LCMV replication at MOI of
1.0 (Fig. 5B), IFN-a was comparable with IFN-b at inducing all
the ISGs examined.
Fig. 6. IRF7 is not required for the development of LCMV-speciﬁc CD8þ T cells or the recruitment of these cells to the brain following infection with LCMV. WT (n¼3)
or IRF7 KO (n¼3) mice were infected i.p. (A–D) or i.c. (E–G) with LCMV. Six (i.p.) or 7 (i.c.) days after infection leukocytes were isolated from the spleen (A–D) or brain (E–G) as
described in the Materials and methods section. Splenocytes were either stained directly with MHC class I tetramer-SA-PE loaded with LCMV-GP33–41 peptide and anti-CD8 (A
and C) or restimulated in vitro for 6 h with LCMV-gp33–41 peptide (B and D) followed by surface staining for CD8 and intracellular staining for IFN-g as described in the
Materials and methods section. Brain-derived leukocytes were stained directly with MHC class I tetramer-SA-PE loaded with LCMV-GP33–41 peptide and anti-CD8 (E and G).
Total number of CD8 T cells in the brain of WT and IRF7 KOmice (F) was enumerated. Data represent mean7SEM. For signiﬁcance: *, po0.05 compared with uninfected mice
as determined by Mann–Whitney U-test.
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is independent of IRF7
Since the development and survival of antiviral CD8þ T cells is
dependent on IFN-I (Aichele et al., 2006; Curtsinger et al., 2005;
Kolumam et al., 2005) we next addressed the question as to
whether the absence of IRF7 might cause defects in the develop-
ment or activation of antiviral CD8þ T cells in the peripheral
organs. To address this question, the number of LCMV-speciﬁc
CD8þ T cells was enumerated in spleens of both groups following
i.p. infection. LCMV infection resulted in a signiﬁcant increase in
the percentage of CD8þ T cells that recognized the LCMV-speciﬁc
MHC class I tetramer in the spleens of both WT and IRF7 KO mice
(Fig. 6A and C) and there was no difference between WT and IRF7KO mice. These results indicated that IRF7 is not required for the
generation of LCMV-speciﬁc CD8þ T cells.
Next the activation of CD8þ T cells after i.p. LCMV infection
was investigated. After re-stimulation in vitro with LCMV-GP33–41
peptide, the number of IFN-gþ CD8þ T cells was analyzed by
ﬂow cytometry. There was a signiﬁcant increase in the percentage
of IFN-gþ CD8þ T cells in spleens (Fig. 6B and D) from infected
WT mice compared with uninfected controls. Furthermore,
infected IRF7 KO mice showed a comparable increase in the
percentage of IFN-gþ CD8þ T cells in the spleen (Fig. 6B and
D). In total these ﬁndings indicate that IRF7 is not required for the
generation of activated LCMV-speciﬁc CD8þ T cells.
In view of the increased survival of IRF7 KO mice following i.c.
infection and our ﬁnding above that expression of IFN-g mRNA
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we next addressed the question as to whether IRF7 deﬁciency
affects the number of LCMV-speciﬁc CD8þ T cells in the brain
following i.c. infection with LCMV. As expected CD8þ T cells were
virtually absent from the brain of sham infected WT and IRF7 KO
mice (Fig. 6F). However, at the maximum clinical disease stage
after ic infection with LCMV, the number of CD8þ T cells in the
brain was signiﬁcantly increased to a similar level in WT and IRF7
KO mice (Fig. 6F). Furthermore, the percentage of CD8þ T cells
that recognized the LCMV-speciﬁc MHC class I tetramer in the
brain was similar between WT and IRF7 KO mice (Fig. 6E and G).
These ﬁndings indicated that following i.c. infection with LCMV,
the total number of CD8þ T cells as well as the subset of these
cells that were LCMV-speciﬁc was not signiﬁcantly altered by the
absence of IRF7.Discussion
Here we studied i.c. and i.p. LCMV infection in mice that were
deﬁcient for IRF7—the key transcriptional inducer of IFN-I gene
expression. Previous studies have established that deﬁciency
either in IFN-I (Sandberg et al., 1994b) or IFN-I signaling (Hofer
et al., 2012; Ou et al., 2001) protects against LCM with failure to
clear the virus and development of a persistent infection. Some-
what surprisingly, and in contrast to these ﬁndings, here we
observed that IRF7 KO mice have an intermediate phenotype
following i.c. LCMV infection, with a delayed onset of LCM and
signiﬁcantly increased survival. Moreover, whether infected i.c. or
i.p., IRF7 KO mice showed an impaired initial control of LCMV
infection with increased virus burden and more widespread virus
tropism, yet, similar to WT mice, these mice cleared the infection,
albeit with a delay. In all, the ﬁndings indicate that in contrast to
IFN-I, the requirement for IRF7 in the host antiviral response to
LCMV is only partial and does not compromise the ability of the
host to mount an antiviral immune response. Our ﬁndings
conﬁrm and extend a recent report in which IRF7 KO mice were
shown to fail to control LCMV replication in the early stages of
infection but were capable of clearing LCMV infection (Zhou et al.,
2012). However, in contrast to the ﬁndings of Zhou and colleagues
(Zhou et al., 2012), we found that IRF7 KO mice were more
resistant to lethal LCM following i.c. infection with LCMV.
The reduced susceptibility to and delay in LCM we observed in
the IRF7 KO mice is likely linked to the decreased ability of these
animals to control the early phase of LCMV infection. The critical
role of the early IFN-I response in limiting LCMV replication and
spread is well established and failure of this response, as occurs
with IFN-I signaling deﬁciency (Hofer et al., 2012; Muller et al.,
1994; Ou et al., 2001) is associated with rapid and exuberant
replication of the virus in most organs. Under these circumstances
of high viral load and lack of IFN-I in which the latter is also
required for the clonal expansion of anti-viral CD8þ T cells
(Aichele et al., 2006; Curtsinger et al., 2005; Kolumam et al.,
2005), it is likely that the anti-viral CD8þ T cells undergo
exhaustion (van den Broek et al., 1995). However, the develop-
ment of LCM and the ability of IRF7 KO mice to clear LCMV
infection indicated that an effective CD8þ T cell response to
LCMV is generated in these animals. Indeed, this was supported
by our ﬁndings here showing that the numbers and activation
state of anti-LCMVGP33–41 CD8þ T cells elicited in the periphery
by LCMV infection in IRF7 KO mice was equivalent to similarly
infected WT mice and conﬁrms recent ﬁndings (Zhou et al., 2012)
reported during preparation of this manuscript. We propose that
the delayed clearance of LCMV from IRF7 KO mice mediated by
the CD8þ T cells is not due to a defect or functional exhaustion inthese cells, rather, most likely is due to the widespread and
increased burden of virus in these animals.
LCMV infection of mice is associated with rapid up-regulation
of IFN-I production (Malmgaard et al., 2002; Merigan et al., 1977).
Recent work has indicated that the systemic production of IFN-a
following LCMV infection in mice is mediated by haematopoietic
cells (Lang et al., 2009). In addition, plasmacytoid dendritic cells
(DC) and non-plasmacytoid DCs as well other cell types including
splenic marginal zone macrophages have been shown to be
important for IFN-I production following LCMV infection (Dalod
et al., 2002; Diebold et al., 2003; Jung et al., 2008; Louten et al.,
2006; Montoya et al., 2005). IRF7 was originally referred to as a
‘‘master regulator of IFN-I responses’’ by Honda et al. (2005).
Previous studies have shown that IRF7 is crucially required for the
induction of IFN-a in mice infected with LCMV-WEHI (Lang et al.,
2009) and LCMV-Traub (Christensen et al., 2012) and our ﬁndings
here conﬁrm this also is the case for LCMV-Arm 53b infection.
Furthermore, the induction of IFN-a has been reported to be
severely impaired following infection of mice with a variety of
other viruses including HSV and EMCV (Honda et al., 2005), WNV
(Dafﬁs et al., 2008) and murine cytomegalovirus (MCMV)
(Steinberg et al., 2009) indicating the seminal role of IRF7 in the
regulation of the IFN-a response to infection across a wide
spectrum of viruses. Nevertheless, our ﬁndings indicate that in
contrast to IFN-a, the systemic IFN-b response to LCMV infection
was largely independent of IRF7 suggesting that the IFN-I
response to LCMV infection in IRF7 KO mice is only partially
impaired. This is further supported by the observations that IRF7
KO mice remained partially susceptible to LCM and were able to
clear LCMV which are not observed in IFN-I signaling deﬁcient
mice (Hofer et al., 2012; Muller et al., 1994; Ou et al., 2001).
The differential dependence of the IFN-I response on IRF7 in
LCMV infection parallels ﬁndings reported for MCMV (Steinberg
et al., 2009) and WNV (Dafﬁs et al., 2008) infection in mice where
IFN-a but not IFN-b production was found to be impaired by the
absence of IRF7. Thus, the signaling pathways in mice that couple
infection with these viruses to the downstream induction of IFN-I
clearly differ for IFN-a versus IFN-b. While the identity of these
pathways remains to be identiﬁed, evidence suggests that in some
cells such pathways may also be independent of IRF3 (Honda
et al., 2005). Interestingly, we observed that in the absence of IRF7
the induction of Ifnb gene expression was blunted in the spleen
but not in the brain while at day 4 postinfection, it was actually
signiﬁcantly higher in the brain of IRF7 KO mice. This differential
tissue response to the absence of IRF7 suggests that the regula-
tory mechanisms that control Ifnb gene expression in LCMV
infection are determined by the local cellular environment. In
support of this notion, analysis of the cells responsible for the
production of IFN-b following LCMV infection in the spleen
suggest that marginal zone macrophages (Louten et al., 2006)
are the principal cells involved, while in the brain, astrocytes and
meningeal membrane cells have been attributed with this func-
tion (Christensen et al., 2012).
The lack of IRF7 was associated with reduced levels of IFN-g
mRNA in the brain at the peak of LCM when compared with WT
mice after i.c. LCMV infection. The basis for this decrease in Ifng gene
expression is not known but did not appear to be due to a general
reduction in the immune response in the brain since the expression
of a number of other proinﬂammatory cytokine and chemokine
genes was increased to similar levels as in infected WT animals.
Moreover, the decreased level of Ifng gene expression was not due to
less CD8þ T cells entering the brain with the total as well as LCMV-
speciﬁc CD8þ T cells being similar in number in WT and IRF7 KO
mice. Since there was a delay in the onset of LCM in the IRF7 KO
mice it is possible that the decreased Ifng gene expression results
from delayed activation of the CD8þ T cells entering the brain but
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systemic induction of both IFN-g mRNA in the spleen and IFN-g
protein in the serum was increased after i.p. LCMV infection in IRF7
KO mice indicating that there is not a general defect in the induction
of IFN-g linked to the absence of IRF7.
The exact contribution of IFN-a versus IFN-b in controlling
LCMV infection in vivo is unknown. We found that the IFN-a
response was absent from IRF7 KO mice and coincided with
increased LCMV tissue burden and we surmised that IFN-a likely
contributes to the early control of LCMV infection. However, direct
comparison of the effectiveness of IFN-a versus IFN-b to inhibit
LCMV infection in vitro revealed that despite having similar listed
speciﬁc activity, IFN-a was signiﬁcantly less potent than IFN-b at
inhibiting LCMV replication. Examination of the ability of these
IFN-I to induce the expression of a number of ISGs also revealed
reduced potency of IFN-a at lower concentrations when compared
with IFN-b. However, at higher concentrations while the level of
ISG expression was similar for both IFN-a and IFN-b, IFN-a
remained markedly less effective at controlling LCMV infection in
the RAW264 cells. Using a combination of the two IFN-I did not
increase the antiviral effects above that found for IFN-b alone
suggesting that the effect of IFN-b is dominant. These data suggest
that in regard to the IFN-a preparation used in our studies, that
LCMV is more sensitive to the antiviral effects of IFN-b rather than
IFN-a. However, there are multiple IFN-a isotypes in the mouse
(Pestka et al., 2004) and it is not known currently which IFN-a
isotypes predominate in LCMV-Arm infection or the relative
potency of these isotypes to inhibit LCMV replication.
We conclude that IRF7 is not required to protect mice from
overwhelming LCMV infection. Our ﬁndings provide clear evi-
dence of an obligatory role for IRF7 in the induction of the IFN-a
but not the IFN-b limb of the host response to LCMV infection.
This partial defect in the IFN-I response to LCMV compromises the
host antiviral response with increased and more widespread
tissue virus burden early in infection and is manifest clinically
with increased resistance of IRF7 KO mice to lethal LCM. The
resistance to lethal LCM is associated with reduced Ifng gene
expression in the brain of IRF7 KO mice suggesting a reduced
activation of anti-LCMV CD8þ T cells that enter the CNS in
normal numbers. Finally, IRF7 is not required for the normal
development of an antiviral CD8þ T cell-dependent immune
response to LCMV-Arm in the periphery where clearance of virus
infection is achieved.Materials and methods
Mice
C57BL/6 wild-type mice were obtained from ARC (Canning
Vale, Western Australia). The IRF7 KO mice (Honda et al., 2005) on
a C57BL/6 background were obtained from Riken Bioresource
Center, Japan. All mice were bred under pathogen free conditions
in the animal facility of the School of Molecular Bioscience, The
University of Sydney, Sydney, Australia. Ethical approval for the
use of all mice in this study was obtained from the University of
Sydney Animal Care and Ethics Committee.
LCMV infection
All mice were aged between 8 and 16 weeks at the time of
infection. For intracranial (i.c.) inoculation, mice were anesthetized
with 100 mg ketamine and 1 mg xylazine per gram bodyweight
prior to injection of 200 pfu of LCMV-Armstrong 53b in 20 ml of
PBS with 1% fetal bovine serum (FBS). Intraperitoneal (i.p.) infec-
tion was performed by injecting 500 pfu of LCMV diluted in 200 mlof PBS with 1 % FBS. Sham-infected mice were used as controls and
received the same volume of PBSþ1% FBS without virus.
Analysis of tissue viral burden
To monitor the viral spread, mice were euthanized at the times
shown and the brain and organs (lung, liver, kidney and spleen)
were harvested and snap-frozen in liquid nitrogen. Total RNA was
extracted from snap-frozen tissue using TriReagent (Sigma-Aldrich,
Castle Hill, AUS) according to the manufacturer’s instruction. The
LCMV-nucleoprotein (LCMV-NP) RNA was measured by RNase
protection assay (RPA) as previously described (Asensio and
Campbell, 1997). To determine the infectious virus titer, snap-
frozen tissues were weighed and homogenized and plaque assay
was performed as described previously (Hofer et al., 2012).
Analysis of IFN levels
Total RNA was extracted from snap frozen tissues as described
above. RPA was performed using IFN-b and IFN-g riboprobes as
described previously (Campbell et al., 1994; Sandberg et al.,
1994a). For serum levels of IFN-a, IFN-b and IFN-g, mice infected
i.p. with LCMV, were anaesthetized and blood collected by cardiac
puncture at the times shown. Blood was clotted at RT for 30 min
before centrifugation at 1000 g for 10 min at 4 1C. The serum
was removed and stored at 80 1C. Commercially available ELISA
kits were used to measure IFN-a (PBL Biomedical Laboratories, NJ,
USA), IFN-b (MyBioSource, CA, USA) and IFN-g (R&D systems, MN,
USA) performed according to the manufacturer’s instructions.
Analysis of cytokine and chemokine gene expression
Total RNA was extracted from brains isolated from sham- or ic-
infected WT and IRF7 KO mice exhibiting end-stage disease and
total RNA extracted as described above. RPA was performed using
CCL1, CCL2, CCL3, CCL5 CCL6, CCL7, CXCL2, CXCL10, IFN-g, IL-1a, IL-
1b and TNF-a riboprobes as described previously (Asensio and
Campbell, 1997; Campbell et al., 1994).
Isolation of leukocytes from the brain
Following i.c. LCMV infection, mice were anesthetized and
perfused intra-cardially using 20 ml ice-cold PBS on day 7 post-
infection. Brains were dissected and processed as described
previously (Getts et al., 2008). Brieﬂy, brains were dispersed,
passed through a coarse metal sieve and digested in collagenase
IV (Sigma-Aldrich) and DNase I (Sigma-Aldrich) for 1 h at 371C.
The reaction was stopped by adding 10% FCS and non-digested
tissue removed by passing the digests through a 70 mm sieve.
After centrifugation for 15 min at 340 g the cell pellet was then
suspended in 30% Percoll (GE Healthcare, Castle Hill, NSW, AUS)
and layered over 80% Percoll. Samples were centrifuged at
1140 g for 25 min at room temperature, and cells at the inter-
face were collected for further analysis by ﬂow cytometry (see
below). Viable cells were counted using trypan blue exclusion
(Sigma-Aldrich).
Isolation of splenocytes
At day 6 postinfection, WT and IRF7 KO mice were euthanized
and spleen removed. Spleen were dispersed and passed through a
70 mm cell strainer. Cells were washed in PBS and then treated
with red blood cell lysis solution (Qiagen, Chadstone center, VIC,
AUS) for 5 min according to the manufacturer’s protocol. Viable
cells were counted using trypan blue exclusion (Sigma-Aldrich).
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For MHC class I tetramer staining, approximately 5105 viable
brain leukocytes or splenocytes cells were stained with iTAGTM
MHC class I tetramer-SA-PE loaded with LCMV peptide GP33–41
(KAVYNFATC) (Beckman Coulter, Fullerton, CA, USA), and anti-CD8
(APC-labeled) (eBioscience) according to the manufacturer’s pro-
tocol and stored at 4 1C until analysis by FACS performed as
described below.
For intracellular IFN-g staining, approximately 5105 viable
splenocytes were incubated for 6 h at 37 1C with 1 mg/ml LCMV-
GP33–41 peptide (Neosystems, Strasbourg, France) in the presence
of BD GolgiPlugTM protein transport inhibitor containing brefeldin
A (BD Biosciences, SJ, CA, USA) and 10 ng/ml recombinant mouse
IL-2 (R&D systems). After incubation, cells were surface stained
with anti-CD8 (APC-labeled). The intracellular staining with anti-
IFN-g (PE-labeled) (eBioscience) was performed according to the
manufacturer’s instructions using a BD cytoﬁx/CytopermTM plus
ﬁxation and permeabilization kit (BD Bioscience). Samples were
acquired on a FACSCalibur (BD Pharmingen, San Jose, CA, USA)
and analyzed using FlowJo software (Version 9.5; Tree Star,
Ashland, OR, USA). Statistical analysis was performed with Prism
4 software (GraphPad, San Diego, CA, USA).
RAW 264.7 cell line infection and IFNa or b treatment
To investigate the efﬁciency of IFN-a and IFN-b to inhibit
LCMV replication, RAW 264.7 cells were infected with LCMV for
1 h at multiplicity of infection (MOI) of 0.5 or 1. After washing
with PBS, the cells were either treated with or without IFN-
aA(Sigma-Aldrich, speciﬁc activity: 7107 U/mg), IFN-bA(Sigma-
Aldrich, speciﬁc activity: 9107 U/mg) or the combination of
IFN-aA and IFN-b for 72 h at the doses shown. The virus content
in the cell supernatants collected at 72 h was determined by
plaque assay as described above. To assess the potency of IFN-a
and IFN-b to induce the expression of ISGs, RAW 264.7 cells were
either treated with or without IFN-aA or IFN-b at the doses
shown for 4 h. Total RNA was extracted as described above and
RPA was performed using PKR and CXCL10 (Asensio et al., 2001),
IRF7 (Ousman et al., 2005) and ISG15 (Wang and Campbell, 2005)
riboprobes as described previously.Acknowledgments
This work was supported in part by project grant (512407) to
ILC from the National Health and Medical Research Council of
Australia. MJH was a postdoctoral fellow from the Deutsche
Forschungsgemeinschaft (DFG HO3298/1-1). WL was the recipient
of an Australian Postgraduate Scholarship. We thank Laura Parker
and Rui Dan Xie for technical assistance and Claire Thompson for
helpful comments on the manuscript.
References
Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U., Vucikuja, S., 2006.
CD8 T cells speciﬁc for lymphocytic choriomeningitis virus require type I IFN
receptor for clonal expansion. J. Immunol. 176, 4525–4529.
Alshariﬁ, M., Mullbacher, A., Regner, M., 2008. Interferon type I responses in
primary and secondary infections. Immunol. Cell Biol. 86, 239–245.
Asensio, V.C., Campbell, I.L., 1997. Chemokine gene expression in the brain of mice
with lymphocytic choriomeningitis. J. Virol. 71, 7832–7840.
Asensio, V.S., Maier, J., Milner, R., Boztug, K., Kincaid, C., Moulard, M., Phillipson, C.,
Lindsley, K., Krucker, T., Fox, H.S., Campbell, I.L., 2001. Interferon-independent,
human immunodeﬁciency virus-1-gp120-mediated induction of CXCL10/IP-10
gene expression by astrocytes in vivo and in vitro. J. Virol. 75, 7067–7077.
Buchmeier, M.J., Welsh, R.M., Dutko, F.J., Oldstone, M.B., 1980. The virology and
immunobiology of lymphocytic choriomeningitis virus infection. Adv. Immu-
nol. 30, 275–331.Campbell, I.L., Hobbs, M.V., Kemper, P., Oldstone, M.B.A., 1994. Cerebral expression
of multiple cytokine genes in mice with lymphocytic choriomeningitis.
J. Immunol. 152, 716–723.
Christensen, J.E., Fenger, C., Issazadeh-Navikas, S., Krug, A., Liljestrom, P., Goriely,
S., Paludan, S.R., Finsen, B., Christensen, J.P., Thomsen, A.R., 2012. Differential
impact of interferon regulatory factor 7 in initiation of the type I interferon
response in the lymphocytic choriomeningitis virus-infected central nervous
system versus the periphery. J. Virol. 86, 7384–7392.
Curtsinger, J.M., Valenzuela, J.O., Agarwal, P., Lins, D., Mescher, M.F., 2005. Type I
IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and
differentiation. J. Immunol. 174, 4465–4469.
Dafﬁs, S., Samuel, M.A., Suthar, M.S., Keller, B.C., Gale Jr., M., Diamond, M.S., 2008.
Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response
and protects against lethal West Nile virus infection. J. Virol. 82, 8465–8475.
Dalod, M., Salazar-Mather, T.P., Malmgaard, L., Lewis, C., Asselin-Paturel, C., Briere,
F., Trinchieri, G., Biron, C.A., 2002. Interferon alpha/beta and interleukin 12
responses to viral infections: pathways regulating dendritic cell cytokine
expression in vivo. J. Exp. Med. 195, 517–528.
Diebold, S.S., Montoya, M., Unger, H., Alexopoulou, L., Roy, P., Haswell, L.E., Al-
Shamkhani, A., Flavell, R., Borrow, P., Reis e Sousa, C., 2003. Viral infection
switches non-plasmacytoid dendritic cells into high interferon producers.
Nature 424, 324–328.
Edelmann, K.H., Richardson-Burns, S., Alexopoulou, L., Tyler, K.L., Flavell, R.A.,
Oldstone, M.B., 2004. Does Toll-like receptor 3 play a biological role in virus
infections? Virology 322, 231–238.
Getts, D.R., Terry, R.L., Getts, M.T., Muller, M., Rana, S., Shrestha, B., Radford, J., Van
Rooijen, N., Campbell, I.L., King, N.J., 2008. Ly6cþ ‘‘inﬂammatory monocytes’’
are microglial precursors recruited in a pathogenic manner in West Nile virus
encephalitis. J. Exp. Med. 205, 2319–2337.
Hofer, M.J., Li, W., Manders, P., Terry, R., Lim, S.L., King, N.J., Campbell, I.L., 2012.
Mice deﬁcient in STAT1 but not STAT2 or IRF9 develop a lethal CD4þ T-cell-
mediated disease following infection with lymphocytic choriomeningitis
virus. J. Virol. 86, 6932–6946.
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y.,
Takaoka, A., Yoshida, N., Taniguchi, T., 2005. IRF-7 is the master regulator of type-I
interferon-dependent immune responses. Nature 434, 772–777.
Jung, A., Kato, H., Kumagai, Y., Kumar, H., Kawai, T., Takeuchi, O., Akira, S., 2008.
Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells
and induces a cytotoxic T-cell response via MyD88. J. Virol. 82, 196–206.
Kang, S.S., McGavern, D.B., 2008. Lymphocytic choriomeningitis infection of the
central nervous system. Front Biosci. 13, 4529–4543.
Kawai, T., Akira, S., 2006. Innate immune recognition of viral infection. Nat.
Immunol. 7, 131–137.
Kim, J.V., Kang, S.S., Dustin, M.L., McGavern, D.B., 2009. Myelomonocytic cell
recruitment causes fatal CNS vascular injury during acute viral meningitis.
Nature 457, 191–195.
Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J., Murali-Krishna, K., 2005.
Type I interferons act directly on CD8 T cells to allow clonal expansion and
memory formation in response to viral infection. J. Exp. Med. 202, 637–650.
Lang, P.A., Cervantes-Barragan, L., Verschoor, A., Navarini, A.A., Recher, M.,
Pellegrini, M., Flatz, L., Bergthaler, A., Honda, K., Ludewig, B., Ohashi, P.S.,
Lang, K.S., 2009. Hematopoietic cell-derived interferon controls viral replica-
tion and virus-induced disease. Blood 113, 1045–1052.
Louten, J., van Rooijen, N., Biron, C.A., 2006. Type 1 IFN deﬁciency in the absence of
normal splenic architecture during lymphocytic choriomeningitis virus infec-
tion. J. Immunol. 177, 3266–3272.
Malmgaard, L., Salazar-Mather, T.P., Lewis, C.A., Biron, C.A., 2002. Promotion of
alpha/beta interferon induction during in vivo viral infection through alpha/
beta interferon receptor/STAT1 system-dependent and -independent path-
ways. J. Virol. 76, 4520–4525.
Marie, I., Durbin, J.E., Levy, D.E., 1998. Differential viral induction of distinct
interferon-alpha genes by positive feedback through interferon regulatory
factor-7. EMBO J. 17, 6660–6669.
Merigan, T.C., Oldstone, M.B.A., Welsh, R.M., 1977. Interferon production during
lymphocytic choriomeningitis virus infection of nude and normal mice. Nature
268, 67–68.
Montoya, M., Edwards, M.J., Reid, D.M., Borrow, P., 2005. Rapid activation of spleen
dendritic cell subsets following lymphocytic choriomeningitis virus infection
of mice: analysis of the involvement of type 1 IFN. J. Immunol. 174,
1851–1861.
Muller, U., Steinhoff, U., Reis, L.F.L., Hemmi, S., Pavlovic, J., Zinkernagel, R.M., Aguet,
M., 1994. Functional role of type I and type II interferons in antiviral defense.
Science 264, 1918–1921.
Ou, R., Zhou, S., Huang, L., Moskophidis, D., 2001. Critical role for alpha/beta and
gamma interferons in persistence of lymphocytic choriomeningitis virus by
clonal expansion. J. Virol. 75, 8407–8423.
Ousman, S.S., Wang, J., Campbell, I.L., 2005. Differential regulation of interferon
regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous
system during viral infection. J. Virol. 79, 7514–7527.
Pestka, S., Krause, C.D., Walter, M.R., 2004. Interferons, interferon-like cytokines,
and their receptors. Immunol. Rev. 202, 8–32.
Samuel, C.E., 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14,
778–809.
Sandberg, K., Eloranta, M.-L., Campbell, I.L., 1994a. Expression of alpha/beta
interferons (IFN-a/b) and their relationship to IFN-a/b-induced genes in
lymphocytic choriomeningitis. J. Virol. 68, 7358–7366.
W. Li et al. / Virology 439 (2013) 152–162162Sandberg, K., Kemper, P., Stalder, A., Zhang, J., Hobbs, M.V., Whitton, J.L., Campbell,
I.L., 1994b. Altered tissue distribution of viral replication and T-cell spreading
is pivotal in the protection against fatal lymphocytic choriomeningitis in mice
after neutralization of IFN-aXb. J. Immunol. 153, 220–231.
Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., Tanaka, N., 1998. Positive
feedback regulation of type I IFN genes by the IFN-inducible transcription
factor IRF-7. FEBS Lett. 441, 106–110.
Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T.,
Katsuki, M., Noguchi, S., Tanaka, N., Taniguchi, T., 2000. Distinct and essential
roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-
alpha/beta gene induction. Immunity 13, 539–548.
Sen, G.C., 2001. Viruses and interferons. Ann. Rev. Microbiol. 55, 255–281.
Seo, Y.J., Hahm, B., 2010. Type I interferon modulates the battle of host immune
system against viruses. Adv. Appl. Microbiol. 73, 83–101.
Steinberg, C., Eisenacher, K., Gross, O., Reindl, W., Schmitz, F., Ruland, J., Krug, A.,
2009. The IFN regulatory factor 7-dependent type I IFN response is not
essential for early resistance against murine cytomegalovirus infection. Eur.
J. Immunol. 39, 1007–1018.Takeuchi, O., Akira, S., 2007. Recognition of viruses by innate immunity. Immunol.
Rev. 220, 214–224.
Taniguchi, T., Ogasawara, K., Takaoka, A., Tanaka, N., 2001. IRF family of transcrip-
tion factors as regulators of host defense. Ann. Rev. Immunol. 19, 623–655.
Tyler, K.L., 2009. Emerging viral infections of the central nervous system. Arch.
Neurol. 66, 939–948.
van den Broek, M.F., Muller, U., Huang, S., Aguet, M., R.M., Z., 1995. Antiviral
defense in mice lacking both alpha/beta and gamma interferon receptors.
J. Virol. 69, 4792–4796.
Wang, J., Campbell, I.L., 2005. Innate STAT1-dependent genomic response of
neurons to the antiviral cytokine alpha interferon. J. Virol. 79, 8295–8302.
Zhou, S., Cerny, A.M., Fitzgerald, K.A., Kurt-Jones, E.A., Finberg, R.W., 2012. Role of
interferon regulatory factor 7 in T cell responses during acute lymphocytic
choriomeningitis virus infection. J. Virol. 86, 11254–11265.
Zhou, S., Cerny, A.M., Zacharia, A., Fitzgerald, K.A., Kurt-Jones, E.A., Finberg, R.W.,
2010. Induction and inhibition of type I interferon responses by distinct
components of lymphocytic choriomeningitis virus. J. Virol. 84, 9452–9462.
